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Abstract
Alzheimer’s disease (AD) is the most common type of dementia and the most common 
neurodegenerative disorder of elderly. It is not an accelerated form of aging but it is 
characterized by distinct temporospatial brain pathological changes, including amyloid 
plaques accumulation, neurofibrillary tangles deposition, synaptic loss and neuronal 
death with gross brain atrophy. These changes result in persistent progressive memory 
and cognitive decline interfering with the usual daily activities. AD is a multifactorial 
disorder results from the interaction of genetic, epigenetic, environmental and lifestyle 
factors. Estrogen, progesterone and androgen effects are important building stones in AD 
pathogenesis, and their effect in brain modulation and development results in different 
gender susceptibility to the disease. These sex hormones whether gonadal or neuros-
teroids (synthesized locally in the brain) play important neuroprotective roles influenc-
ing the individual’s vulnerability to AD development, rate of mild cognitive impairment 
(MCI)/AD conversion and speed of AD progression. Despite the little therapeutic impli-
cations of hormonal replacement therapy in AD treatment, yet this topic still represents 
a challenging hopeful way to construct a strategy for the development of personalized, 
gender-specific AD management.
Keywords: Alzheimer’s disease, sex hormones, neurosteroids, estrogens, progesterone, 
androgens
1. Introduction
Alzheimer’s disease (AD) is the most common type of dementia and a key determinant of 
healthcare costs. It is an age-related neurodegenerative disorder, and due to increased peo-
ple life expectancy, AD becomes one of the most burdensome threats to public health and a 
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grand international research challenges. It is a system-specific brain disease affecting discrete 
neurons in a nearly consistent temporospatial pattern and is characterized by progressive 
memory decline and persistent cognitive impairment enough to interfere with the person’s 
performance of the usual daily activities.
1.1. History
The gender difference in the cognitive and neurobehavioral performance had been noticed 
since ancient time which may be the origin of the popular legend (men are from Mars, women 
are from Venus and had met here in Earth) [1]. The concept of age-related cognitive decline 
was well known since antiquity, which progressed through the ages till reached the term 
dementia. The link between female sex and dementia had also noticed since a very long 
period and this made Jean Etienne Esquirol put menstrual disorders and sequelae of deliv-
ery as direct causes of dementia in his book Des Maladies Mentales [2, 3]. In 25 November 
1901, the German neurologist, Dr. Alois Alzheimer admitted a patient presented by recent 
cognitive decline to the public mental asylum in Frankfurt. Surprisingly, this first description 
was on a 51-year-old lady named Auguste Deter, who experienced marked memory decline, 
fear of people and became jealous of her husband in the last year preceded her admission 
in Frankfurt asylum by Dr. Alois Alzheimer and Dr. Hermann P. Nitsche. Later, the patient 
developed severe behavioral abnormalities, delusions, disorientation of time and place, hal-
lucinations and severe language difficulties. In 1906, Auguste died and her autopsy revealed 
gross brain atrophy and microscopically increased silver staining by using Bielschowsky 
method, which later named amyloid plaques and neurofibrillary tangles (NFTs) [4].
1.2. Epidemiology
Dementia affects about 47 million people worldwide, and this number is expected to double 
every 20 years due to increased life expectancy. AD is the leading cause of dementia account-
ing for about 30% of early onset cases before the age of 50 years and 60–80% of late onset ones 
either as pure or mixed form [5]. It is one of the commonest causes of prolonged disability in 
old age, the sixth cause of death in USA globally and the fifth cause for seniors above the age 
of 65. Old age is the most important AD risk with estimated prevalence of 3% in people aged 
65–74 years, 17% between 75 and 84 years and 32% in those >85 years [6, 7].
AD disproportionately affects both sexes, with females have 2–3 times higher incidence of AD 
than males of the same age. The age-specific risk of developing AD is almost twofold greater 
in women than men, 17.2% vs. 9.1% at 65 years and 28.5% vs. 10.2% at 75 years. The incidence 
of amnestic mild cognitive impairment (MCI) is equal both in male and female, denoting that 
females take shorter MCI/AD transitional state with rapid conversion to manifest AD [5, 8, 9].
1.3. Pathology
AD is not an accelerated form of aging but it is characterized by distinct cellular and molecu-
lar pathological changes, including amyloid plaque deposition, NFTs accumulations, synaptic 
loss and neuronal death with gross brain atrophy.
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1.3.1. The amyloid hypothesis
The amyloid cascade theory with the resultant extracellular amyloid plaque aggregation is the 
leading one for AD pathogenesis. Amyloid plaques are aggregates of amyloid beta (Aβ) pep-
tide derived mainly from the cleavage of a transmembrane protein named amyloid precursor 
protein (APP) by the sequential action of two aspartyl protease enzymes, β- and γ-secretases 
(amyloidogenic pathway) in which the APP is firstly cleaved by β-secretase to soluble APP 
and residual C-terminal segment that is further digested by the γ-secretase to Aβ-40/42 seg-
ments. The insoluble Aβ aggregates start to appear 15–25 years prior to the onset of cognitive 
decline or tau pathology, and their formation is triggered by enhancement of the amyloido-
genic pathway with increasing the pool of soluble Aβ production, which in turn aggregate to 
form monomeric, oligomeric, protofibrils and finally mature insoluble Aβ [10]. Under normal 
circumstances, the ratio of Aβ-42: Aβ-40 is 1:9 and increase in this ratio due to either aber-
rant production (increased γ-secretase activity) or clearance (abnormal microglial activities) 
is the cause of Aβ accumulation as the former has a high tendency to aggregate. The amyloid 
aggregates spark a sequence of events that lead to AD development including neuronal injury 
and synaptic loss. It is generally accepted that brain β-amyloid deposition is relatively diffuse, 
and there is non-linear correlation between the density of mature Aβ aggregate and severity 
of AD, which denotes that soluble Aβ oligomers per se are neurotoxic and cause synaptic 
dysfunction even in the absence of insoluble aggregate [11, 12].
1.3.2. Neurofibrillary tangles
Tau pathology, including NFTs, neuritic plaques and neuropil threads intraneural deposition 
is assumed to be the consequence of amyloid accumulation. NFTs are intraneural misfolded 
twisted paired helical filaments, which accumulate to form intracellular deposits composed of 
hyperphosphorylated tau protein that concentrates in the inner side of the cell membrane, but 
when the neurons die, NFT may migrate to other healthy or less affected neurons or may be 
found extracellular. Tau is essential for NMDA-dependent long-term potentiation and AMPA-
dependent long-term depression and acts as autophagy regulator by inhibiting histone deacety-
lase-6 enzyme. Thus, tauopathies result in marked synaptic disturbances and impaired selective 
autophagic clearance. Tau has more than 25 serine, threonine and tyrosine residue sites, which 
can be phosphorylated by specific protein kinases and phosphatases [13]. Genetic or acquired 
Figure 1. Photomicrography of Alzheimer’s disease pathology using Bielschowsky stain demonstrating neurofibrillary 
tangles and amyloid plaques.
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induced dysfunctions result in tau hyperphosphorylation, misfolding and fibrillar formation 
ending in NFTs deposition. On the other hand, tau dephosphorylation is regulated by protein 
phosphatase 2A enzyme, which activity is impaired in AD. NFTs accumulation starts several 
years after Aβ deposition but still before AD clinical manifestations and its accumulation dense 
and distribution is directly proportional with the severity of AD cognitive decline. NFTs deposi-
tion usually follows a stepwise progression typically starting in the transentorhinal cortex, the 
entorhinal cortex, hippocampus, medial temporal cortex and lastly other areas of the neocortex 
[14, 15] (Figure 1).
1.3.3. Microglia and neuroinflammation
It is well known that the density of β-amyloid deposition is not proportional with the severity 
of AD cognitive decline making the amyloid hypothesis alone is not sufficient to explain the 
whole AD pathological cascade and in turn the possible role of additional pathogenetic fac-
tors, including neuroinflammation and vascular amyloidosis. The neuroinflammatory theory 
was supposed after identification of activated microglia within the vicinity of the amyloid 
plaques, which number was proportional with the size of the plaques. At the same time, several 
microglial expressed genes were associated with AD predisposition, including TREM2, CD33, 
CR1, CLU, CD2AP, EPHA1, ABCA7 and INPP5D. Under normal circumstances, microglial 
activities are modulated by several neuroimmune regulatory proteins, including insulin-like 
growth factor-1, brain-derived neurotrophic factor, transforming growth factor-b and nerve 
growth factor, which help in slowdown and resolving the inflammatory process [16].
Microglia have no role in Aβ production; however, they act as Aβ scavengers as they play 
major roles in its clearance either directly through phagocytosis or indirectly via the secretion 
of several enzymes, including insulin degrading enzyme, neprilysin, matrix metalloprotein-
ase-9 and plasminogen. At the same time, microglia regulate synaptic network remodeling 
(synaptic pruning) and neural circuit maintenance [17].
In AD, chronic reactivation and excessive proliferation of microglia result in the production 
of inflammatory mediators, including reactive oxygen species, interleukin-1, interferon-γ and 
tumor necrosis factor-alpha. This imbalanced microglial function results in aberrant synaptic 
pruning, pathological synaptic stripping, neuronal loss, enhancing the endothelial response to 
hypoxia with impaired blood-brain barrier (BBB) stability, disturbed Aβ clearance, increased 
levels of phosphorylated tau protein, promoting NFTs accumulation and, consequently, cog-
nitive decline. Microglia also transport amyloid and tau from one brain area to another; thus, 
they play a major role in spatial AD progression. Microglia are candidate for the action of 
sex hormones, and they express abundant sex hormone receptors. These receptors modulate 
microglial activities producing potent anti-inflammatory actions that resist AD development 
and progression [18, 19].
1.3.4. Vascular theory
Diabetes, hypertension, smoking and heart diseases are associated with increased risk of 
AD. This concept resulted in the emergence of the AD vascular theory, which can explain 
why aging is the major risk of AD as vascular dysfunction is considered as a universal feature 
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of aging and why AD progression increases after cerebral ischemic events like stroke and 
transient ischemic attacks. Cerebral amyloid angiopathy (CAA) is present in more than 75% 
of autopsy confirmed AD brains especially in mixed AD/vascular dementia where the vas-
cular risk factors predominate. Cerebral microvascular compromise is more common among 
subjects having the APOE4 allele making them at increased risk of AD development. CAA 
represents imbalanced Aβ production and clearance with consequent deposition within the 
basement membrane of the leptomeningeal vessels, intracerebral arteries and arterioles, and 
less frequently in capillaries and veins [20].
Amyloid deposition in and around the blood vessel wall impairs its endothelial integrity and 
disturbs the BBB leading to Aβ trapping in the CSF and its diminished clearance to the venous 
circulation. At the same time, CAA disrupts the microvascular homeostasis leading to chronic 
cerebral parenchymal hypoperfusion with focal ischemia, microinfarcts, release of inflamma-
tory mediators, oxygen-free radicals, loss of nitric oxide bioavailability and mitochondrial 
dysfunction. The net result is neurotoxicity, reduced neural plasticity, neural apoptosis and 
synaptic loss [21]. Sex hormone receptors are heavily expressed in the cerebral blood vessels 
and exert very important actions to keep the vascular integrity and prevent chronic ischemic 
hypoperfusion through promoting endothelial relaxation by increasing the production/activity 
of nitric oxide and prostacyclin and at the same time prevent vascular smooth muscle contrac-
tion by inhibiting intracellular Ca2+ influx and antagonize the actions of protein kinases [22].
1.3.5. Monoaminergic and cholinergic abnormalities
Synaptic failure is an important factor in the cognitive manifestations of AD before mani-
fest neuronal loss takes place. The neurochemical changes in AD include extensive seroto-
nergic denervation in the hippocampus and neocortex, depletion of the cholinergic neurons 
in the basal forebrain, loss of >70% of noradrenergic locus coeruleus neurons, reduction of 
dopamine, dopamine metabolites and dopamine receptors, histaminergic tuberomammillary 
nucleus degeneration and impaired melatonin secretion and action in the pineal body and 
suprachiasmatic hypothalamic nucleus, respectively [23].
Glutamate is a non-essential amino acid but it is one of the most important excitatory synaptic 
neurotransmitter as most of the CNS myelinated axons are glutamatergic. AD patients show 
aberrant increase in extracellular glutamate, which enhances tau pathology and enhances glu-
tamate receptors expressed oligodendroglia to transport tau from one brain area to another 
leading to AD spatial progression. At the same time, there is a reciprocal relationship between 
glutamate and Aβ as soluble amyloid oligomers as well as insoluble Aβ deposits increases 
the extracellular glutamate concentration resulting in AMPA (α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionate) and NMDA (N-methyl-d-aspartate) receptors dysfunction, disturbed 
synaptic pruning and impaired synaptic plasticity with promotion of long-term synaptic 
depression and inhibition of long-term synaptic potentiation leading to cognitive decline espe-
cially memory domain. At the same time, NMDA receptor inhibition promotes amyloidogenic 
γ-secretase activities and inhibits non-amyloidogenic α-secretase with the resultant increase 
in Aβ production and accumulation and vice versa. Many studies revealed protective effects 
of sex hormones against glutamate-induced neurotoxicity through inhibition of glutamate 
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release by reducing the activities of lactate dehydrogenase, inhibiting intracellular Ca2+ influx, 
exerting antioxidant action and enhancing mitogen-activated protein kinase action [24, 25].
1.4. Genetics and epigenetics of AD
Genetic predisposition to AD is very complex although positive family history is a common 
patients’ finding. The rare early onset AD constitutes less than 1% of cases and often transmit-
ted as autosomal dominant and fully penetrant inheritance. Common affected genes include 
APP (genes encoding γ-secretase complex), presenelin-1 (PSNL1) and presenelin-2 (PSNL2) 
gene mutation in chromosomes 21, 14 and 1, respectively. Overexpression of these genes 
results in increased production of the highly hydrophobic fibrillogenic longer Aβ-42 and on 
the expense of the relatively shorter Aβ-40 [23].
In late onset AD, apolipoprotein E series, especially APOE4, is the major genetic risk as >60% 
of AD patients harbor at least one APOE4 allele. APOE is a lipid-binding cholesterol trans-
porter protein essential for maintenance of myelin and neuronal membranes, synaptogenesis 
and dendritic reorganization. Three APOE isoforms exist in humans: APOE2, APOE3 and 
APOE4. Heterozygous and homozygous APOE4 are at increased risk of significantly lower 
age of AD onset and higher rate of AD development by about 4 and 15 folds than other allele 
types. At the same time, males with APOE4 are more liable to develop MCI than others. 
APOE4 allele expression interacts with the sex hormones leading to increased risk of AD in 
women than men of the same age. APOE4 expression results in decreased soluble APPα/Aβ 
ratio, reduced Sirtuin T1 expression (NAD+-dependent deacetylases that attenuate amyloido-
genic), triggered tau phosphorylation and induced neuronal apoptosis [26].
Many studies revealed that people with a rare missense mutation (rs75932628-T) in the gene 
encoding TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) are at increased risk 
of developing AD 2–3 folds than others possibly due to reduced clearing abilities of their 
microglia to Aβ and apoptotic cells [10]. At the same time, other studies suggested a pos-
sible role of epigenetic changes and aberrantly expressed micro-RNAs (miRNAs) in the 
pathogenesis of AD through disturbing neurogenesis, synaptic plasticity, synaptogenesis 
and neuronal network preservation as well as enhancing Aβ production and neuroinflam-
mation [27]. Both epigenetics and miRNAs are influenced by sex hormone receptor activa-
tion, and they are potentially versatile and adaptive, which gives a challenging hope for 
novel therapeutic approaches in AD management. The epigenetics represents alterations in 
genetic functions without changing DNA sequence and constitutes an interface of genetic/
environmental factors interplay, e.g. DNA methylation, histone modifications, non-coding 
RNAs regulation and higher order chromatin remodeling [28]. MiRNAs are 18–22 nucleo-
tide long, non-coding RNAs that are involved in post-transcriptional suppression of gene 
expression [29].
1.5. Clinical signs and symptoms
Dementia of Alzheimer’s type typically presents by episodic memory impairment, which 
gradually progresses to interfere with the activities of daily living. Memory impairment is 
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usually followed by other cognitive domains declines which vary according to the pattern 
of cortical progression, including apathy, loss of interest in hobbies, sleep disturbances, 
impaired spatial and temporal navigations, inability to solve problems due to executive 
dysfunction, behavioral changes, difficulty in using common instruments due to apraxia, 
language difficulties, incontinence and high dependency on others [7, 11].
The AD cognitive decline is usually preceded by a period of mild cognitive impairment 
(MCI) in which the individual retains his usual daily activities but has subnormal per-
formance in cognitive neuropsychological testing. Many researchers reported a prodro-
mal stage of subjective cognitive decline in which the person experiences worsening in 
his memory and/or cognitive performance despite the normal objective performance in 
standardized cognitive neuropsychological tests [30]. Atypical AD types start by non-
amnestic manifestations but have the same pathological hallmarks include logopenic 
aphasia type, dysexecutive type, parietal dominant and frontal dominant atrophy sub-
types [31, 32].
1.6. Investigations and biomarkers
It is generally accepted that AD pathological changes begin decades before the appearance 
of dementia symptoms and this leads to the introduction of the term preclinical AD, which 
is defined as biomarker evidences of AD pathological changes in a cognitively healthy indi-
vidual. The current challenge is to develop reliable biomarkers for early pre-dementia AD 
diagnosis to maintain longer patients’ independence and prepare the floor for the discovery 
of disease modifying agents including hormonal replacement therapy before irreversible neu-
ral damage takes place [11].
The ADNI-2 (Alzheimer Disease Neuroimaging Initiative-2) established CSF biomarkers 
include reduced CSF Aβ-42 and elevated total and phosphorylated tau-181, which are very 
accurate in prediction of MCI/AD conversion with 85% sensitivity and 90% specificity. 
Novel but still non-approved CSF biomarkers include high Aβ oligomers and neurogranin 
levels [33].
Figure 2. Brain MRI of a 56 years old female with early Alzheimer Disease showing medial temporal atrophy in T1 axial 
section (left), decreased right entorhinal cortex volume (middle) and right hippocampus volume (right) in coronal 3D 
spoiled gradient magnetic resonance images.
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Blood biomarkers include high plasma homocysteine, high serum angiotensin converting 
enzyme activities and low plasma levels of the obesity-related hormone leptin [20]. Other ongo-
ing research biomarkers include prostate-specific antigen complexed to α1-antichymotrypsin, 
pancreatic prohormone, clusterin and fetuin B [34].
The imaging biomarkers that can predict MCI/AD conversion are usually directed to mea-
sure the neural and synaptic densities in the commonly affected cortical areas. In volumetric 
MRI, manual and/or automated techniques can detect hippocampus and entorhinal cortex 
atrophy with concomitant dilatation of the temporal horns of the lateral ventricle. Other 
early neuroimaging biomarkers include task-free functional MRI (measures network failure 
quotient), diffusion tensor imaging (DTI) MRI, SPECT, FDG-PET, amyloid PET and tau PET 
[35] (Figure 2).
2. Sex hormones in normal cognition
Better keep progestogen as it is a wider term than progesterone and this is clarified in the 
section of progesterone are synthesized from cholesterol by the action of aromatase enzyme, 
and they play important roles in shaping the neural functions and behavior throughout all 
stages of human life. The sex steroid hormones are potent regulators of neuronal survival and 
function in multiple CNS regions during normal development, aging and in some neurode-
generative disorders including AD. In aging individuals, low levels of gonadal sex hormones 
are associated with decline in neurogenesis especially in the hippocampus with the resultant 
age-dependent memory decline and executive function difficulties [36].
2.1. Gender cognitive variability
Over a long time, obvious sexual dimorphism in adult human brain was observed with females 
harbor larger frontal and medial paralimbic cortices, while males exhibit bigger medial fron-
tal cortex, amygdala and hypothalamic volumes. This gender difference is mainly due to vari-
ability in sex chromosome and sex hormone neuronal action. Genetic studies revealed that 
X-chromosome carry genes which expressions enhance visuospatial, executive and/or social 
cognitive tasks, whereas genes on Y-chromosome are more responsible for behavioral sexual 
differentiation [37].
At the same time, there is different gender cognitive performance starting during the early 
neonatal period and persists throughout human survival. This sex difference may be the base 
of the striking variable susceptibilities to various cognitive disorders in men and women [38]. 
Under normal circumstances, there is non-significant sex difference in global cognitive perfor-
mance, but generally, males are better in mathematics and 3D spatial tests, while females are 
superior in autobiographic, episodic memory and verbal tests. Regarding spatial navigation, 
males perform better in allocentric strategy (world-centered object-to-object spatial relations) 
but females excel in egocentric navigation (self-centered subject-to-object spatial relations). 
This different cognitive performance is universal and evident in humans and animals which 
weaken the suggestion that environmental factors or gendered socialization are the causes of 
these gender variations [39, 40].
Sex Hormones in Neurodegenerative Processes and Diseases152
2.2. Estrogen actions in normal cognition
Estrogen is the primary female sex hormone, which regulates fundamental physiological pro-
cesses in both reproductive and nonreproductive organs, including the CNS. The brain can 
synthesize estrogens (neuroestrogens) either by the aromatization of androgens or via a series 
of enzymatic steps from the precursor of all steroids, cholesterol. This neuroestrogen plays 
major roles in sexual differentiation of brain in both male and female. Four natural types of 
estrogens exist: estrone (E1; a weak estrogen and the main postmenopausal type), estradiol 
(E2; the most potent endogenous estrogen and the main type during the reproductive age), 
estriol (E3; very weak estrogen and hardly detected in non-pregnant females) and estetrol (E4; 
secreted only during pregnancy) [41].
Estrogens can cross the cell membrane lipid bilayer to bind to the estrogen receptors (ER), 
which are of two types: nuclear and membrane ER. The nuclear ER are either ERα or ERβ, 
which are responsible for the estrogen genomic action through regulation of various tran-
scriptional gene expression mechanisms. The brain contains both types of nuclear ER, which 
are abundant in the hippocampus, pyramidal cells and glial tissue [42]. The membrane estro-
gen receptors (mERs) are G protein-coupled and ligand-gated ion channels, including GPER1 
(previously known as GPR30), ER-X and Gq-mER, which are responsible for the rapid non-
genomic actions of estrogen that is initiated within minutes after estrogen administration 
(estrogen neurotransmitter actions) due to recruitment and activation of kinase-dependent 
signaling pathways. Membrane ER are abundant in the neocortex and their activation results 
in increased activity of nitric oxide synthase and Ca2+ influx to the cells through N-methyl-d-
aspartate (NMDA) receptor-mediated mechanism [43, 44].
The cellular mechanisms underlying estrogen CNS actions are still uncertain due to the differ-
ent estrogen expression in both sexes and in different brain areas, but it is generally accepted 
that estrogens usually promote neurogenesis, exert neuroprotective actions and support neu-
ronal survival by antiapoptotic action, stimulating nerve growth factor and brain-derived 
neurotrophic factor [45]. Estrogens also improve neuronal plasticity especially in the hippo-
campus, increase cerebral blood flow by enhancing endothelial derived nitric oxide and pros-
tacyclin pathways, regulate neural mitochondrial functions (both types of ER are expressed 
in the mitochondria) especially in stressful conditions by stimulating anti-apoptotic proteins 
and decrease free radical production. At the same time, estrogen exerts anti-inflammatory 
actions by reducing the expression of astrocyte to chemokines, promoting the maturation of 
oligodendrocyte precursor cells and improve their ability for CNS repair, which enhances the 
growth and differentiation of axons and dendrites and prevents axonal loss and demyelin-
ation [46].
Estrogens also have well-documented direct cognitive and behavioral actions, and their post-
menopausal depletion been associated with cognitive decline and increased risk of AD. The rapid 
estrogen non-genomic actions are important for hippocampal memory consolidation and hippo-
campal-dependent spatial navigation memory and improve learning performance, novel objects 
recognition and object placement tasks when administered before the cognitive tests. At the same 
time, estrogens improve choline acetyltransferase activity, promote serotonergic neuronal func-
tion and stimulate dopamine release in the caudate, prefrontal cortex, nucleus accumbens and 
dorsal raphe nucleus, which in turn enhance age-related learning and memory declines [36, 47].
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2.3. Progesterone actions in normal cognition
Progesterone is a steroid hormone and it is most active natural progestogen, synthesized in 
the gonads, placenta, adrenal glands and CNS (neurosteroids). It has many reproductive 
and non-reproductive functions, including regulation of a wide range of brain functions [48]. 
Progesterone has a lipophilic structure, which can cross the cell membrane to interact with its 
specific intracellular progesterone receptors (PRs) expressed throughout the brain without sex 
difference with special higher expression in the hypothalamus, hippocampus, frontal cortex, 
medial amygdaloid nucleus, norepinephrine neurons of the nucleus tractus solitaries and cere-
bellum. Progesterone exerts its CNS actions through regulation of gene expression, modulation 
of neurotransmitter systems and epigenetic actions as well as enhancing estrogen actions [49].
PRs are either nuclear type (PR-A and PR-B), transmembrane PR (7TMPRβ) or membrane-
associated 25-Dx PR (PGRMC1). Nuclear PRs are ligand inducible transcription factors 
that regulate target genes expression and play important roles in sexual brain differentia-
tion, reproductive behavior, neuroprotection, neurogenesis, Schwan cell activities and their 
myelination programs, proliferation of neural progenitor cells and the release of the brain-
derived neurotrophic factor important for cell differentiation and survival. Progesterone also 
has anti-inflammatory actions through regulation of the activities of astrocytes, microglia and 
oligodendrocytes [50, 51].
Transmembrane PRs are G protein-coupled receptors responsible for the rapid action of 
progesterone, and when activated, they block the activity of adenylyl cyclase, including 
enhancement of mitochondrial functions and regulation of cell viability. At the same time, 
progesterone alters dopaminergic and GABAergic system activities in many brain regions 
mainly the hippocampus, amygdala and fusiform gyrus enhancing the memory and learning 
performances [52, 53].
2.4. Androgen actions in normal cognition
Androgens are very important sex steroids that exert cognitive functions in both males and 
females as they not only regulate the CNS development but also help to maintain its proper 
function from infancy to adulthood [54]. It is generally accepted that androgens play a pivotal 
role in cognitive performance and their depletion or signaling inhibition (in normal aging 
or anti-androgen hormonal therapy in cancer prostate) results in dysfunction in androgen-
responsive tissues, including the brain and consequently deleterious cognitive impairment. 
At the same time, discontinuation of anti-androgen in cancer therapy restores cognitive per-
formance especially verbal memory [55].
The CNS action of androgens is mediated either directly through stimulation of androgen recep-
tors (ARs) (nuclear receptors regulating target genes expression at transcriptional level) or indi-
rectly after conversion to estrogen by the action of aromatase enzyme. ARs are highly expressed 
in the septum pellucidum, stria terminalis, preoptic area, ventromedial hypothalamus and 
cerebellum where they regulate the sexual reproductive behaviors [56, 57]. Neuroandrogens 
production had detected in the hippocampus where they modulate the hippocampal structure 
specifically CA1 and CA3 areas. In the medial amygdala and prefrontal cortex, androgens exert 
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important roles in cognitive function regulation through promoting neuroprotection (anti-glu-
tamate action) and neurogenesis, improving neuronal survival and anti-apoptotic effect (regu-
lating mitochondrial genome activities and suppressing reactive oxygen species), modulating 
hippocampal synaptic plasticity, enhancing remyelination and exerting anti-inflammatory 
action by regulating astrocytic and oligodendrocytic activities [58]. Beside the delayed genomic 
effects of androgens, non-genomic rapid actions are mediated by trans-membrane G-protein-
coupled ARs, which stimulations increase the intracellular Ca2+ influx and result in improved 
inhibitory avoidance task, spatial learning and memory performance [59, 60].
Androgens especially anabolic androgen steroids (AAS) are not always neurobehaviorally 
beneficial, and their short-term use results in aggressive and manic behaviors, whereas their 
long-term use is associated with impairment of decision making, behavioral flexibility, cogni-
tive control and spatial memory [61, 62].
3. Brain responses variability to sex hormones
The neurocognitive actions of sex hormones are not simple but several factors may interact 
to control their beneficial effects including the inter-balance between their levels as well as 
the age and sex of the individual. In pregnancy, simultaneous increase in progesterone and 
estrogens results in impaired mood and decreased memory [63]. At the same time, sex hor-
mones seem to play their major neuromodulatory action in early person’s prepubertal life 
with subsequent decrease in the neuronal sensitivity to their actions with advancement of age. 
Some studies revealed that prepubertal sex hormones have permanent effects in individual’s 
behaviors and cognition including spatial abilities. Early pubertal testosterone administration 
to gonadectomized male Syrian hamsters resulted in their attaining adult mating behaviors 
while administration in late puberty did not give the same results denoting that neurons are 
highly sensitive to the organizational effect of sex hormones at certain age with decreased 
sensitivity later after passage of this time [64–66]. On the other hand, brain estrogen expression 
was reduced in adult female mice previously exposed to stress in adolescence but not in early 
adulthood which concludes that adolescent stresses suppress estrogen activities and interfere 
with its organizational actions to attain adult mating behavior. From these results, we can con-
clude that the individual’s susceptibility to many neurodegenerative disorders including AD 
may be attained since early life and we may not be able to reverse it easily later [67, 68].
4. Sex hormones in MCI and Alzheimer’s disease
Alzheimer’s disease is a heterogenous disorder with multiple variants and wide variety 
of manifestations, which result from the interactions between multiple etiological factors, 
including genetic, epigenetic, environmental and lifestyle factors. Neuronal action of sex hor-
mones represents one of the well-defined AD pathogenetic factors and may represent a hope 
to understand the biology of sex-dependent variability in AD predisposition and in turn leads 
to the development of personalized, gender-specific AD management.
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4.1. Sex hormones and MCI
The concept of MCI had received much attention nowadays for early detection of those can-
didates to AD conversion which open a gate for future disease modifying agents including 
hormonal therapy before irreversible neuronal damages take place. MCI is a clinical condition 
lies between normal aging and dementia in which the cognitive dysfunctions are greater than 
expected for age but is not severe enough to significantly interfere with the daily life or warrant 
the diagnosis of dementia [8, 69]. MCI is classified to amnestic (am-MCI) and non- amnestic 
(nam-MCI) types. In the former, memory impairment is the dominating manifestation, and 
in the latter, non-memory cognitive domain is the affected one (language, attention, execu-
tive function, visual-spatial). Amnestic MCI is termed multiple domain if another cognitive 
domain is affected, whereas nam-MCI becomes multiple domain if more than one cognitive 
non-memory domain is affected. People with am-MCI are more liable to develop AD [11, 70].
The prevalence of am-MCI is about 8.5–25.9 per 1000 of general population and 10–20% of 
those above the age of 60 years; 10–15% of am-MCI persons will develop AD compared to 
1–2% of nam-MCI people. Several clinical and biochemical markers had been studied to be 
used as predictors of MCI/AD progression. In general, women have a higher prevalence of 
nam-MCI but most metanalytic studies showed non-significant gender difference in the prev-
alence of am-MCI, which means that women take shorter time to convert from am-MCI to 
manifest AD [71, 72].
4.2. Sex hormones and Alzheimer’s disease
One of the most common observations associated with AD onset is decreased levels of sex 
hormones, including estrogens, progesterone and androgens, pointing the potential role of 
these hormones in AD pathogenesis and the possible benefits of their targeting in AD man-
agement strategies.
4.2.1. Estrogens and Alzheimer’s disease
Estrogen neuroprotective actions in AD are well documented by decades of researches show-
ing that women used estrogen supplements or those with late menopause are at significantly 
decreased risk of AD development. On the other hand, early menopause because of increased 
sex hormone-binding globulin is associated with higher risk of AD in later life [73]. Estrogens 
exert anti-AD actions through different mechanisms including inhibition of tau deposition 
and Aβ accumulation. The former action is exerted through inhibition of tau hyperphosphor-
ylation and promotion of tau dephosphorylation in an estrogen receptor-dependent mode 
through inhibition of protein kinases and promotion of protein phosphatase 2A enzyme 
activities, respectively [13, 74]. Estrogens inhibit Aβ accumulation by several mechanisms, 
one of which is decreasing Aβ production by enhancement of non-amyloidogenic APP path-
way through activation of α-secretase enzyme that cleaves APP to soluble APP-α peptides and 
shorter membrane-attached C-terminal segment. The latter is further digested by γ-secretase 
to non-toxic P3 and C59 segments. Other estrogen actions include inhibition of β-secretase 
(amyloidogenic pathway) and stimulation of APP-containing vesicle budding by trans-Golgi 
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network [75]. Estrogens also promote Aβ clearance by stimulation of microglial Aβ phagocy-
tosis and enzymes involved in Aβ degradation, including metalloproteases-2 and -9, insulin-
degrading enzyme and neprilysin [76].
At the same time, estrogens exert anti-AD actions by increasing dendritic spine densities, pro-
moting synaptogenesis, inhibiting the neurotoxic effects of oxidized low-density lipoproteins 
and glutamate, improving mitochondrial functions and enhancing the hippocampal cholin-
ergic neurotransmitter system. Estrogens also regulate the epigenetic DNA methylation and 
miRNAs biogenesis especially in the hippocampus and thus master the genes expressions 
both transcriptionally and post-transcriptionally, which in turn play pivotal roles in enhance-
ment of neuroprotection and prevention of neurodegeneration. Estrogen actions seem to be 
age dependent with obvious dysregulation in old-aged people. At the same time, estrogens 
have neuroprotective actions through increasing the expression of antiapoptotic Bcl-xL and 
Bcl-w and suppressing the expression of proapoptotic Bim, which lead to prevention of neu-
ronal loss from Aβ toxicity [77–80].
Women are at increased risk of AD due to age-related sharp decline in sex steroid hormones 
and spending a large proportion of their life in the postmenopausal period because of increased 
their life longevity with the resultant prolonged hypoestrogenic state and its negative neuro-
logical consequences. Studies showed that postmenopausal women with AD had lower estra-
diol (E2) and estrone (E1) levels in both blood and CSF compared to normal controls. Moreover, 
female CSF-E2 level is positively correlated with CSF-Aβ level and cerebral glucose metabolism 
in the left hippocampus PET scan, which denotes that they are at increased risk to develop 
AD. In short-term studies, transdermal estrogen administration is associated with increased 
attention, verbal and visual memories; however, long-term studies failed to slow down AD 
progression or adding benefits to rivastigmine therapy in postmenopausal women [47, 81].
The neuroprotective effect of estrogen is not the same in both sexes as brain E1 and E2 levels 
have no relations with Aβ accumulation in males pointing to different gender expression of sex 
steroid hormones. At the same time, estrogen administration in male to female cross sex sub-
jects results in significant decreases in the hippocampal volume despite producing neurogene-
sis, which means that the estrogen AD risk prevention in males is negligible [82, 83] (Figure 3).
4.2.2. Progesterone and Alzheimer’s disease
Studies in progesterone neuroprotective actions against AD predisposition are not so plenty 
like those on estrogens but despite this, it is generally accepted that progesterone has a direct 
neuroprotective action while its indirect actions against AD development by regulating the 
neuroestrogen effects are matter of controversy as in some studies, progesterone enhances 
estradiol neuroprotective actions and in others antagonizes them beside reducing the cerebral 
blood flow [84].
The direct progesterone protecting actions against AD development and/or progression 
include regulation of β-amyloid metabolism by reducing Aβ production and decreasing 
the pool of soluble Aβ by enhancement of the non-amyloidogenic α-secretase pathway, 
decreasing Aβ accumulation through modulation of γ-secretases activities and increasing Aβ 
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clearance by enhancing insulin-degrading enzyme expression and downregulation of 
β-secretase gene expression [85, 86]. At the same time, progesterone reduces tau hyperphos-
phorylation and the serum level of endogenous progesterone is inversely correlated with 
tau accumulation, and at the same time, progesterone administration in transgenic AD mice 
improved cognitive performance in object recognition and T-maze task [87].
4.2.3. Androgens and Alzheimer’s disease
Androgens have neuroprotective effects against AD in both males and females. Many studies 
had detected lower testosterone level in men with AD relative to normal age-matched control 
both in the blood and CSF. At the same time, APOE4 allele, which is a major risk of late onset 
AD, is associated with significantly lower level of circulating testosterone [88]. In accordance 
with these results, the Baltimore Longitudinal Study on Aging had detected significantly 
lower testosterone level 5–10 years in healthy men prior to their development of clinically 
manifest AD compared to those who did not develop AD [89].
Short-term testosterone administration improves cognitive functions in MCI and AD patients 
possibly through non-genomic transmembrane ARs activation [90, 91]. The long-term direct 
genomic action of androgens results in reduction of Aβ accumulation through enhance-
ment of non-amyloidogenic APP pathway and promoting Aβ clearance by stimulation of 
Aβ-degrading enzyme action. Postmortem studies had shown that brain levels of testoster-
one were inversely correlated with cerebral soluble Aβ, which precedes insoluble fibrillar 
Aβ accumulation. These androgenic anti-amyloid actions are exerted in both sexes [92, 93]. 
Androgens can also indirectly reduce Aβ accumulation either through enhancing the estrogen 
pathway or through hypothalamo-hypophyseal-gonadal axis where they inhibit the release 
of gonadotropin luteinizing hormone secretion by the negative feedback, and it is well known 
that the latter hormone increases Aβ production by enhancement of APP/β-secretase initiated 
amyloidogenic pathway [94].
Figure 3. Estrogen anti-Alzheimer’s neuroprotective actions.
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Males are subjected to andropause due to age-dependent high level of sex hormone-bind-
ing globulin with subsequent decrease in androgen levels and effects. Sex hormone-binding 
globulin is significantly higher in AD patients than age- and sex-matched control resulting in 
functional impairments of androgen-responsive tissues including the brain with consequent 
increase in AD risk [73]. Male andropause occurs very slowly over a long period of time 
where total androgen level starts to decline in thirties in a rate of 0.2–1% per year, while free 
testosterone decreases in a higher rate (2–3% yearly). This slowly gradual andropause relative 
to the rapid menopause may be one of the explanations of decreased male gender AD risk, 
delayed male MCI/AD conversion and slower AD cognitive deterioration [78, 95].
5. Sex hormone therapy trials for Alzheimer’s disease
Based on the abundant data supporting the numerous neuroprotective actions of sex hor-
mones in ameliorating many pathological processes occurring in AD, hormonal replacement 
therapy (HRT) seems to be theoretically beneficial but the translation of this hypothesis to 
practice met a lot of difficulties which made the use of HRT in AD management still a matter 
of skepticism [36, 94]. The values of female estrogens and progesterone replacement therapies 
carry controversial results, which are mainly dependent on the timing, dose and duration of 
their application to the AD predisposed individual. Promising results were only attained on 
early HRT initiation at a close menopause temporal proximity and any delayed administra-
tion may even give counterproductive bad consequence. This time limit of proper HRT initia-
tion resulted in introduction of the term the critical window of intervention or the window of 
opportunity which describes the time after which HRT become worthless. HRT has not the 
same effect in all genotypes but it is found to be more beneficial in people with APOE2 and 
APOE3 genotypes than APOE4 [96–100]. At the same time, some studies revealed that the 
protective effect of HRT against AD is only achieved in long-term users (>10 years), while 
short-term therapy had no AD preventive actions pointing to the need of long-term HRT use 
to gain significantly beneficial AD protection [101, 102]. The need for long-term use of conven-
tional HRT opens a new obstacle due to the high cardiovascular risks which in some instances 
may overwhelm the anti-AD cognitive benefits. This makes AD patients in ultimate need for 
future introduction of new hormonal drugs with little side effects [103, 104]. At the androgenic 
level and despite their numerous anti-AD neuroprotective actions, the long-term androgens 
use carries many neurological and extra-neurological risks including decreased dendritic 
reorganization and spine density in the limbic regions after initial increase due to increased 
glutamate turnover and neurotoxicity in amygdala structures with functional impaired con-
nectivity with areas involved in cognitive functions [105, 106].
6. Conclusions and future prospect
Alzheimer’s disease is a complex multifactorial neurodegenerative disorder resulted from 
dysregulation of many biological processes at multiple levels in a specific neuronal temporo-
spatial pattern. Sex hormones, including estrogens, progesterone and androgens, play crucial 
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CNS modulatory functions and their disturbances result in impairment of neuroprotection, 
neurogenesis, synaptogenesis, synaptic plasticity and myelination as well as abnormal glial 
cell activities. The sharp decrease of neurosteroids influences in menopause relative to the 
slow andropause makes females sex at increased risk of AD development, rapid MCI/AD 
conversion and rapid course of cognitive deterioration. Trials used sex hormones as a disease 
modifying neuroprotective anti-AD agents revealed that their possible beneficial effect can be 
achieved only by early HRT before the beginning of critical window of intervention and the 
therapy must continue for long time which may put the treated individuals at increased risk 
of cardiovascular complications.
So, what is nowadays considered normal menopausal or andropausal sex hormones’ declines 
may be sufficient triggers irreversible neuropathological changes which latter on progress to 
AD in susceptible individuals, and it is the time to use these changes as early AD biomarkers 
in high risk persons and in turn correct them before the onset of the window of opportunity by 
safe and effective HRT for long-term use and sufficient to produce significant AD prophylaxis.
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